BreezoMeter

QuantHealth is an organization that produces software using artificial intelligence technology for drug development data. This software is utilized for conducting patient-focused medication simulations, with the aim of expediting and reducing the risks associated with drug development. By merging data from various sources within clinical and drug development fields, the company's software can forecast how patients will respond to both existing and innovative treatments. This enables pharmaceutical and biotechnology clients to conduct different versions of their clinical trials, enhancing trial design and boosting the chances of successful trials. As a result, QuantHealth aids in uncovering new clinical prospects and optimization strategies.

Microbot Medical is a company that creates innovative medical devices using micro-robotic technology. They are dedicated to improving surgical outcomes for patients by allowing more physicians to treat more patients. Currently, they are working on the development of two products: the Self Cleaning Shunt for hydrocephalus treatment and the TipCAT endoscope for colonoscopy procedures.

Nurami Medical is committed to creating a surgical scaffold platform that promotes the repair, regeneration, and safe healing of soft tissues after internal surgeries. The production technology utilized by Nurami Medical is founded on the electrospinning technique.

Senseera specializes in developing liquid biopsy blood tests for the early detection and monitoring of human diseases.

Inspira Technologies is a cutting-edge medical technology company that specializes in the acute respiratory care sector. Their unique ART technology aims to meet the demand for treatment that supports patients with acute respiratory conditions without the need for mechanical ventilation while they are conscious and breathing independently.

MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health.

Vensica Medical is a medical device company that is designing and developing and Ultrasound catheter for the treatment of bladder cancer. Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica’s device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.

TruLeaf Medical develops easy-to-use solutions for Transcatheter Mitral Valve Replacement (TMVR).

MedicannX is a company that specializes in the medical cannabis industry.

Established in October, 2012, Magenta Medical Ltd. is a privately-owned company focused on creating innovative medical devices for treating both acute and chronic heart failure.

NanoPass is where cutting-edge technology intersects with healthcare innovation. We pioneer revolutionary solutions in intradermal delivery, reshaping the landscape of therapeutic and medical aesthetic procedures using our proprietary technology towards a precise, safe, and efficient future. Our MicronJet™ intradermal delivery product platform has redefined the standard of care. Join the Intradermal precision revolution! NanoPass's IP-backed product, the MicronJet (registered with the US FDA, the EU, Brazil, China, Australia and other countries), is the most advanced hollow microneedles device available today. Its excellent performance is backed by more than 50 clinical studies. The Company has concluded the world's first intradermal pandemic flu vaccine study and additional seasonal flu studies, demonstrating equivalent or superior immunogenicity to standard delivery using only 20% of the dose. The company is backed by prominent Israeli and US investors Ă˝and medical device companies, including IHCV, Ofer Hi-Tech, D-Partners, WFD Ventures and Elcam Medical. NanoPass recently closed a new round of financing, led by Israel Health Care Ventures (IHCV) NanoPass is continuously engaged in joint clinical development with top pharmaceutical companies, to demonstrate the benefits of its technology for various indications.

Endoron Medical fosters an endovascular stitch, similar to a gadget for the powerful therapy of a stomach aortic aneurysm.